Should you buy Novanta (NOVT)?
Updated
Novanta is a high-quality scientific instruments company with a perfect Piotroski score, excellent free cash flow conversion of 162%, and four consecutive earnings beats, but negative price momentum with a falling on-balance volume and a price already above analyst consensus targets reduce near-term appeal.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Novanta converts 162% of net income into free cash flow and has a perfect Piotroski F-Score of 9 out of 9, indicating exceptionally strong business quality with cash generation well in excess of reported earnings and robust across all financial health dimensions. Quality breakdown | Free cash flow as a percentage of net income remains above 130% and Piotroski F-Score stays at 8 or 9 over the next 12 months. | →Stable |
| CounterHigh free cash flow relative to net income in scientific instruments companies can partly reflect low current R&D intensity, and maintaining the score requires sustained investment in product innovation. | ||
Novanta has beaten earnings estimates in all 4 of the last 4 quarters, with an average positive surprise of 4.5%, and earnings estimates have been trending upward, suggesting the company is executing well in its medical and industrial technology markets. Earnings | Earnings beat streak extends to at least 2 more quarters with positive surprises above 3%. | →Stable |
| CounterAverage earnings surprises of only 4.5% are modest and could easily disappear with any cost pressure or demand softness in the medical device manufacturing sector. | ||
On-balance volume is declining, the momentum score of 3.5 is well below the gate threshold of 4.5, and volume distribution shows sellers are more active than buyers, indicating institutional selling pressure despite strong fundamentals. Momentum breakdown | On-balance volume reverses to a rising trend and momentum score recovers above 4.5 within 3 months. | →Stable |
| CounterNovanta remains above its 200-day moving average, and the momentum weakness may reflect a temporary rotation out of high-multiple industrials rather than fundamental deterioration. | ||
Novanta converts 162% of net income into free cash flow and has a perfect Piotroski F-Score of 9 out of 9, indicating exceptionally strong business quality with cash generation well in excess of reported earnings and robust across all financial health dimensions.
→Stable- Expectation
- Free cash flow as a percentage of net income remains above 130% and Piotroski F-Score stays at 8 or 9 over the next 12 months.
CounterHigh free cash flow relative to net income in scientific instruments companies can partly reflect low current R&D intensity, and maintaining the score requires sustained investment in product innovation.
Novanta has beaten earnings estimates in all 4 of the last 4 quarters, with an average positive surprise of 4.5%, and earnings estimates have been trending upward, suggesting the company is executing well in its medical and industrial technology markets.
→Stable- Expectation
- Earnings beat streak extends to at least 2 more quarters with positive surprises above 3%.
CounterAverage earnings surprises of only 4.5% are modest and could easily disappear with any cost pressure or demand softness in the medical device manufacturing sector.
On-balance volume is declining, the momentum score of 3.5 is well below the gate threshold of 4.5, and volume distribution shows sellers are more active than buyers, indicating institutional selling pressure despite strong fundamentals.
→Stable- Expectation
- On-balance volume reverses to a rising trend and momentum score recovers above 4.5 within 3 months.
CounterNovanta remains above its 200-day moving average, and the momentum weakness may reflect a temporary rotation out of high-multiple industrials rather than fundamental deterioration.
▸ Show 1 more pillar▾ Show fewer
The current price of $156.63 is approximately 5% above the analyst consensus price target of $168.41 less a 15% haircut, meaning buyers at current prices are entering above where the analyst consensus models suggest fair value lies.
→Stable- Expectation
- Analyst consensus price target is revised upward above $175 within 6 months as growth continues to be delivered.
CounterHigh-quality technology companies with perfect Piotroski scores frequently trade above analyst targets because earnings growth compounding makes consensus targets perpetually lag market prices.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Novanta converts 162% of net income into free cash flow and has a perfect Piotroski F-Score of 9 out of 9, indicating exceptionally strong business quality with cash generation well in excess of reported earnings and robust across all financial health dimensions.
Trip ifFree cash flow falls below 100% of net income for 2 consecutive quarters.
- P2Novanta has beaten earnings estimates in all 4 of the last 4 quarters, with an average positive surprise of 4.5%, and earnings estimates have been trending upward, suggesting the company is executing well in its medical and industrial technology markets.
Trip ifEarnings surprise falls below 0% in at least 2 of the next 4 quarters.
- P3On-balance volume is declining, the momentum score of 3.5 is well below the gate threshold of 4.5, and volume distribution shows sellers are more active than buyers, indicating institutional selling pressure despite strong fundamentals.
Trip ifPrice drops below $140 while on-balance volume remains in a declining trend.
- P4The current price of $156.63 is approximately 5% above the analyst consensus price target of $168.41 less a 15% haircut, meaning buyers at current prices are entering above where the analyst consensus models suggest fair value lies.
Trip ifPrice rises above $175 while analyst consensus target remains below $165.
How the engine reached this verdict
TrendMatrix's engine output for Novanta Inc. (NOVT) is STRONG_BUY_WAIT with medium conviction, score 5.5/10 at $152.00. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
The engine's suggested entry zone is $147.22, currently 3.2% above entry. Target $168.41, stop $136.91, asymmetric R:R 2.06. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 0.5% of portfolio at this asymmetry level (medium-conviction tier).
On the bull side: Strong earnings beat streak (4/4); Earnings estimates trending UP; Strong growth profile. On the bear side: Analyst target reached - limited upside remaining. Active engine warnings: V8: Target reached (-2.1% upside), L3:NEWS_MOD=+1: HOLD_IF_HOLDING → STRONG_BUY_WAIT, V9 Gate Failed: ASYMMETRY:-0.2=NEGATIVE.
BUY_NOW requires reward-to-risk (NEGATIVE) to clear OR price pulling back to the entry zone of $147.22 with asymmetry crossing 2.5. The verdict flips to HOLD if overall score deteriorates by ~0.7 from sentiment or technical drift.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates NOVT — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸Earnings estimates trending UP
- ▸Strong growth profile
Bear case
- ▸Analyst target reached - limited upside remaining